PET CT Re-Planning NSCLC (4DCT-PET)

Study Overview
=================
Brief Summary
-----------------
This study will see whether the addition of more frequent planning CTs during the course of radiation, and of Positron Emission Tomography (PET), a diagnostic test similar to CT, prior to and during a course of radiation may provide information that could potentially be used during the treatment to improve the initial radiation plan.

Official Title
-----------------
Prospective Study of CT and PET Imaging During a Course of Radical Radiotherapy to Determine the Dosimetric Benefits of Re-Planning in Non-Small Cell Lung Cancer

Conditions
-----------------
Lung Cancer, Non-Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: PET/CT Scans


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age equal to or more than 18 years old Patients with NSCLC consenting for radiotherapy to the primary tumor and / or mediastinal / hilar lymph nodes. Prescription doses should be 60Gy or higher. Chemo-RT patients of any stage of NSCLC Patients with a measurable tumor on CT scan. Patients who are able to lie supine for two consecutive 25 minutes sessions. Exclusion Criteria: Trimodality patients who will have surgery within 2 months post RT Previous radiotherapy to intended treatment volumes. Patients with recurrent disease Active malignancy other than lung cancer Pregnancy Failure to provide written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: PET/CT Scans|PET Imaging requires the use of an investigational drug, a radioactively-labelled sugar called 18F-Fluorodeoxyglucose (FDG). FDG is glucose labelled with a radioactive fluorine atom. It is given by intravenous injection and is particularly absorbed by cancer cells. The radioactive signal given off by the FDG can then be detected by the PET scanner providing an image of the cancer (or tumour).|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GTV volumes | The ratio of the GTV volumes defined using 4D CT (GTV4DCT) planning scans is a prognostic parameter for NSCLC. | 2 weeks post RT treatment | 
| GTV volumes | The ratio of the GTV volumes defined using 4D CT (GTV4DCT) planning scans is a prognostic parameter for NSCLC | 4 weeks post RT Treatment | 
| GTV volumes | The ratio of the GTV volumes defined using 4D CT (GTV4DCT) planning scans is a prognostic parameter for NSCLC | 7 weeks post RT Treatment | 
| GTV volumes | he ratio of the GTV volumes defined using 4D CT (GTV4DCT) planning scans is a prognostic parameter for NSCLC | 3 months post RT treatment | 
| GTV volumes | The ratio of the GTV volumes defined using FDG PET (GTVPET) planning scans | 2 weeks post RT Treatment | 
| GTV Volumes | The ratio of the GTV volumes defined using FDG PET (GTVPET) planning scans | 4 weeks post RT Treatment | 
| GTV Volumes | The ratio of the GTV volumes defined using FDG PET (GTVPET) planning scans | 7 weeks post RT Treatment | 
| GTV volumes | The ratio of the GTV volumes defined using FDG PET (GTVPET) planning scans | 3 months post RT treatment |